Table 1.
Demographic data of total patients and ADCTA and reference groups.
| Variable | Total (n = 47) | ADCTA (n = 27) | Reference (n = 20) | ||||
|---|---|---|---|---|---|---|---|
| Number | Ratio (%) | Number | Ratio (%) | Number | Ratio (%) | ||
| Sex | Male | 20 | 42.55 | 10 | 37.04 | 10 | 50 |
| Female | 27 | 57.45 | 17 | 62.96 | 10 | 50 | |
| Age (years) | ≥57a | 23 | 48.94 | 16 | 59.25 | 7 | 35 |
| <57 | 24 | 51.06 | 11 | 40.75 | 13 | 65 | |
| R/T | No | 12 | 25.53 | 1 | 3.7 | 11 | 55 |
| Yes | 35 | 74.47 | 26 | 96.3 | 9 | 45 | |
| TMZ | No | 13 | 27.66 | 0 | 0 | 13 | 65 |
| Yes | 34 | 72.34 | 27 | 100 | 7 | 35 | |
| GKS | No | 31 | 65.96 | 18 | 66.67 | 13 | 65 |
| Yes | 16 | 34.04 | 9 | 33.33 | 7 | 35 | |
| CCRT | No | 22 | 48.89 | 8 | 29.63 | 14 | 70 |
| Yes | 23 | 51.11 | 19 | 70.37 | 6 | 30 | |
| ADCTA | No | 20 | 42.55 | 0 | 0 | 20 | 100 |
| Yes | 27 | 57.45 | 27 | 100 | 0 | 0 | |
| KPS | <70 | 18 | 38.3 | 10 | 37.04 | 8 | 40 |
| ≥70 | 29 | 61.7 | 17 | 62.96 | 12 | 60 | |
| Tumor resection | Gross total | 25 | 53.19 | 14 | 51.85 | 11 | 55 |
| Non-total | 22 | 46.81 | 13 | 48.15 | 9 | 45 | |
| Isocitrate dehydrogenase 1 mutation | No | 43 | 93.01 | 24 | 87.5 | 19 | 94.74 |
| Yes | 4 | 6.99 | 3 | 12.5 | 1 | 5.26 | |
| Methylguanine-DNA methyltransferase methylation | No | 7 | 14.89 | 4 | 14.81 | 3 | 15 |
| Yes | 40 | 85.11 | 23 | 85.19 | 17 | 85 | |
Twenty-seven patients fitting the inclusion criteria were randomly assigned to the ADCTA group, and the remaining 20 patients were assigned to the reference group.
R/T, radiotherapy, completed without delay or interruption; TMZ, temozolomide; GKS, gamma knife; CCRT, concomitant chemoradiotherapy; ADCTA, autologous dendritic cell tumor antigen immunotherapy; KPS, Karnofsky Performance Score; postoperation, pre-ADCTA vaccination.
aModified according to American Association of Neurological Surgeons: GBM occurs between the ages of 45 and 70 years.